BFRIW
Biofrontera Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$0.00
+0.00%Price chart
Sep 30Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30
Key dataOct 30, 2026
Open$0.10
From 52W high−99.30%
Volume37763.00
Market cap$15087.43
P/E (TTM)—
P/S (TTM)0.0x
Div yield—
Key dataOct 30, 2026
Open
$0.10
From 52W high
−99.30%
Volume
37763.00
Market cap
$15087.43
ValuationView details →
P/E (Fwd)
0.0x
EV/EBITDA
−0.5x
P/E (TTM)
—
RSI (14)
24.5
MomentumView details →
1D Return
+0.00%
YTD Return
−98.56%
Similar companies
Latest newsMore news →
Biofrontera Inc. submitted a supplemental new drug application to the FDA seeking to expand Ameluz red-light photodynamic therapy labeling to actinic keratoses on the full body, covering treatment fields of up to approximately 240 cm² with an adjusted illumination protocol.23d agoBiofrontera announced that the FDA approved its Ameluz red-light photodynamic therapy for the treatment of superficial basal cell carcinoma.47d agoBiofrontera Inc. reported its financial results for the second quarter of 2026, highlighting a 33% revenue growth.79d ago